tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Harrow appoints Fank Mullery as CEO, ImprimisRx

Harrow (HROW) announced leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as CEO and Bridseida Cruz has been appointed as Head of Quality of ImprimisRx. Most recently, Mullery served as President of Sintetica US, where he spearheaded the creation of the company’s U.S. subsidiary – taking it from concept to full commercialization, while successfully launching its first five sterile injectable products. Cruz is an executive with over 25 years of experience leading quality and operations in 503B outsourcing, pharmaceutical, and medical device organizations.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1